The Need: Enhancing Surgical Precision with Anti-TAG-72 Imaging Agents

Colorectal carcinoma is a significant medical challenge, with a high incidence rate in the USA. Current surgical approaches, along with external imaging technologies, have limitations in accurately detecting cancerous tissues, leading to incomplete tumor removal and lower survival rates. Surgeons require real-time, precise guidance during operations to detect cancerous sites not apparent on preoperative imaging. To address these limitations, a new technology using anti-TAG-72 imaging agents has been developed, offering superior intraoperative detection capabilities.

The Technology: Anti-TAG-72 Imaging Agents

The anti-TAG-72 imaging agents are composed of an anti-TAG-72 binding moiety and a first detectable label emitting fluorescent light detectable on a clinical optical NIRF imager primarily above 800 nm. The anti-TAG-72 binding moiety consists of an antibody or TAG-72 binding antibody fragment, such as 3E8.scFv (SEQ ID NO: 1) or 3E8.scFv.Cys (SEQ ID NO: 2) modified to include a terminal cysteine residue. Additionally, the anti-TAG-72 imaging agents can incorporate a second detectable label, such as a radiolabel.

Commercial Applications:

• Optical Surgical Navigation (OSN): Anti-TAG-72 imaging agents can be administered intraparetoneally or intravenously for precise optical surgical navigation, guiding surgeons to cancerous tissues during colorectal tumor removal surgeries.

• Tumor Removal with Optical Surgical Navigation: The technology enables surgeons to perform tumor removal with real-time optical guidance, improving the accuracy and completeness of the surgical procedure.

• Assaying Tumor Viability: By using anti-TAG-72 imaging agents, surgeons can assess tumor viability before tumor removal, determining the feasibility of surgical intervention and optimizing treatment decisions.

Benefits/Advantages:

• Enhanced Surgical Precision: Anti-TAG-72 imaging agents provide real-time, intraoperative guidance, allowing surgeons to detect and remove cancerous tissues with higher precision, minimizing the risk of recurrence.

• Improved Patient Outcomes: The technology's ability to detect otherwise occult cancer sites and ensure complete resection contributes to improved long-term survival rates and better patient outcomes.

• Efficiency and Time Savings: By offering rapid detection capabilities, the technology streamlines surgical procedures, reducing the time required for manual measurements, and ensuring wider surgical field coverage.

In conclusion, the revolutionary anti-TAG-72 imaging agents provide a cutting-edge solution for the challenges faced during colorectal carcinoma surgeries. With their ability to enhance surgical precision, improve patient outcomes, and offer efficient real-time guidance, this technology promises to transform the landscape of colorectal cancer treatment, elevating the standard of care for patients and surgeons alike.